Alteration in 11 Beta-Hydroxysteroid Dehydrogenase Type-2 (HSD11B2) Gene as A Potential Candidate Parameter for Early Detection of Intrauterine Growth Restriction (IUGR) Events

Louis Fabio Jonathan Jusni, Patricia Patricia, Brigitte Leonie Rosadi

Abstract


Intrauterine Growth Restriction (IUGR) incidence in Indonesia ranks in the top 10 of the highest in Asia. It is the main perinatal death cause. IUGR also impairs fetal neurodevelopment, which can affect the development of children until later ages. Lack of 11β-hydroxysteroid dehydrogenase type-2 (11β-HSD2) enzyme is influenced by changes in the coding gene, HSD11B2, one of IUGR's causes. The main diagnostic method of IUGR at this time is by using Doppler ultrasound. However, Doppler ultrasound has several limitations as many cases are not detected. Its clinical predictive value in various women is poor, as Doppler ultrasound is not recommended for use in the first trimester, detection of abnormalities in the second trimester seems to be too late for helpful interventions. The study aim is to present an overview concerning HSD11B2 gene alteration in an non-invasive prenatal testing (NIPT) as a possible diagnostic parameter for early detection in IUGR infants. This literature review is based on selected articles and studies taken from the Pubmed, Proquest, and EBSCO databases. A total of 4 studies reported the tendency for DNA methylation and decreased expression of the HSD11B2 gene in IUGR cases. Changes in the HSD11B2 gene have the potential to become a diagnostic parameter in the early detection of infants with IUGR. Further study and investigation of this possibility are needed.

Keywords: intrauterine growth restriction, HSD11B2, early detection, diagnostic, non-invasive prenatal testing


Full Text:

PDF

References


Giuliano N, Annunziata ML, Tagliaferri S, Esposito FG, Imperato OC, Campanile M, et al. IUGR management: new perspectives. J Pregnancy. 2014; 2014: 620976, CrossRef.

Sharma D, Shastri S, Sharma P. Intrauterine growth restriction: antenatal and postnatal aspects. Clin Med Insights Pediatr. 2016; 10: 67-83, CrossRef.

Unterscheider J, O'Donoghue K, Daly S, Geary MP, Kennelly MM, McAuliffe FM, et al. Fetal growth restriction and the risk of perinatal mortality-case studies from the multicentre PORTO study. BMC Pregnancy Childbirth. 2014; 14: 63, CrossRef.

Hasmasanu M, Bolboaca S, Baizat M, Drugan T, Zaharie G. Neonatal short-term outcomes in infants with intrauterine growth restriction. Saudi Med J. 2015; 36(8): 947-53, CrossRef.

Poljak B, Agarwal U, Jackson R, Alfirevic Z, Sharp A. Diagnostic accuracy of individual antenatal tools for prediction of small-for-gestational age at birth. Ultrasound Obstet Gynecol. 2017; 49(4): 493-9, CrossRef.

Lee S, Walker SP. The role of ultrasound in the diagnosis and management of the growth restricted fetus. Australas J Ultrasound Med. 2010; 13(3): 31-6, CrossRef.

Ernst SA, Brand T, Reeske A, Spallek J, Petersen K, Zeeb H. Care-related and maternal risk factors associated with the antenatal nondetection of intrauterine growth eestriction: a case-control study from Bremen, Germany. Biomed Res Int. 2017; 2017: 1746146, CrossRef.

Pinto A, Pinto F, Faggian A, Rubini G, Caranci F, Macarini L, et al. Sources of error in emergency ultrasonography. Crit Ultrasound J. 2013; 5(Suppl 1): S1, CrossRef.

Dondorp W, de Wert G, Bombard Y, Bianchi DW, Bergmann C, Borry P, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet. 2015; 23: 1438-50, CrossRef.

Skrzypek H, Hui L. Noninvasive prenatal testing for fetal aneuploidy and single gene disorders. Best Pract Res Clin Obstet Gynaecol. 2017; 42: 26-38, CrossRef.

Marsit CJ, Maccani MA, Padbury JF, Lester BM. Placental 11-beta hydroxysteroid dehydrogenase methylation is associated with newborn growth and a measure of neurobehavioral outcome. PLoS One. 2012; 7(3): e33794, CrossRef.

Wynne-Edwards KE, Edwards HE, Hancock TM. The human fetus preferentially secretes corticosterone, rather than cortisol, in response to intra-partum stressors. PLoS One. 2013; 8(6): e63684, CrossRef.

Albu AR, Anca AF, Horhoianu VV, Horhoianu IA. Predictive factors for intrauterine growth restriction. J Med Life. 2014; 7(2): 165-71, article.

Börzsönyi B, Demendi C, Pajor A, Rigó J Jr, Marosi K, Agota A, et al. Gene expression patterns of the 11β-hydroxysteroid dehydrogenase 2 enzyme in human placenta from intrauterine growth restriction: the role of impaired feto-maternal glucocorticoid metabolism. Eur J Obstet Gynecol Reprod Biol. 2012; 161(1): 12-7, CrossRef.

Burton GJ, Fowden AL. The placenta: a multifaceted, transient organ. Philos Trans R Soc Lond B Biol Sci. 2015; 370(1663): 20140066, CrossRef.

Stirrat L, Just G, Homer N, Andrew R, Norman J, Reynolds R. Glucocorticoids are lower at delivery in maternal, but not cord blood of obese pregnancies. Sci Rep. 2017; 7(1): 10263, CrossRef.

Grow by WebMC [Internet]. Fetal Doppler [cited 11 September 2021]. Available from: https://www.webmd.com/.

Bhoil R, Kaushal S, Sharma R, Kaur J, Sharma T, Thakur R, et al. Color Doppler ultrasound of spiral artery blood flow in mid first trimester (4-8 weeks) in cases of threatened abortion and in normal pregnancies. J Ultrason. 2019; 19(79): 255-60, CrossRef.

Sheiner E, Abramowicz JS. A symposium on obstetrical ultrasound: is all this safe for the fetus? Clin Obstet Gynecol 2012; 55(1): 188-98, CrossRef.

Helmy S, Bader Y, Koch M, Tiringer D, Kollmann C. Measurement of thermal effects of Doppler ultrasound: an in vitro study. PLoS One. 2015; 10: e0135717, CrossRef.

Sari B, Zahra A, Tasti G, Maritska Z. Healing the fundamental unit of heredity (gene therapy): current perspective and what the future holds. Mol Cel Biomed Sci. 2021; 5(2): 62-7, CrossRef.

Yau M, Haider S, Khattab A, Ling C, Mathew M, Zaidi S, et al. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency. Proc Natl Acad Sci USA. 2017; 114(52): E11248-56, CrossRef.

Bertulli C, Hureaux M, De Mutiis C, Pasini A, Bockenhauer D, Vargas-Poussou R, et al. A rare cause of chronic hypokalemia with metabolic alkalosis: case report and differential diagnosis. Children (Basel). 2020; 7(11): 212, CrossRef.

Zhao Y, Gong X, Chen L, Li L, Liang Y, Chen S, et al. Site-specific methylation of placental HSD11B2 gene promoter is related to intrauterine growth restriction. Eur J Hum Genet. 2014; 22(6): 734-40, CrossRef.

Xiao X, Zhao Y, Jin R, Chen J, Wang X, Baccarelli A, et al. Fetal growth restriction and methylation of growth-related genes in the placenta. Epigenomics. 2016; 8(1): 33-42, CrossRef.

Norwitz ER, Levy B. Noninvasive prenatal testing: the future is now. Rev Obstet Gynecol. 2013; 6(2): 48-62, article.

Kosicka K, Siemiątkowska A, Główka FK. 11β-hydroxysteroid dehydrogenase 2 in preeclampsia. Int J Endocrinol. 2016; 2016: 5279462, CrossRef.

Woolcock J, Grivell R. Noninvasive prenatal testing. Aust Fam Physician. 2014; 43(7): 432-4, article.

Sifakis S, Koukou Z, Spandidos DA. Cell-free fetal DNA and pregnancy-related complications (review). Mol Med Rep. 2015; 11(4): 2367-72, CrossRef.

Yin A, Peng C, Zhao X, Caughey B, Yang J, Liu J, et al. Noninvasive detection of fetal subchromosomal abnormalities by semiconductor sequencing of maternal plasma DNA. Proc Natl Acad Sci USA. 2015; 112(47): 14670-5, CrossRef.




DOI: https://doi.org/10.21705/mcbs.v5i3.214

Indexed by:

                     

                    

            


Cell and BioPharmaceutical Institute